WOK has become one of the most violent short-squeeze setups on the Nasdaq this week — the stock up 379% in five sessions, the borrow market seized, and short sellers sitting on one of the most painful positions in the small-cap universe.
The lending picture tells the story most starkly. Short interest in WORK Medical Technology Group has exploded from roughly 61,000 shares to 846,000 in the space of two trading sessions — a 1,290% weekly increase — now representing 88% of the free float. That is an almost structurally impossible level of short concentration for a stock with this kind of price momentum. Availability has collapsed to zero: every share in the lending pool is currently committed, meaning the borrow market is fully seized. Cost to borrow hit 637% annualised on May 12 — up from 35% just two weeks ago, and up more than 1,655% over the week. To put that differently: borrowing $10,000 of stock for a year would cost over $63,000 in fees at current rates. The ORTEX short score confirms the extremity of the setup, jumping from 66 on May 1 to 81 at the close of last week — ranking in the first percentile of all names on ORTEX for short positioning intensity, and in the first percentile on availability tightness.
The price action has been equally extreme. WOK closed at $6.66 on May 12, up 70% in a single session and up over 412% for the trailing month. Notably, the stock triggered a circuit-breaker halt to the upside during Tuesday's session before pulling back — a classic mechanical signal of short-side forced buying colliding with thin float liquidity. The company's market capitalisation remains tiny at roughly $8 million, which amplifies every incremental move in borrow demand. The news catalyst that lit the fuse was a May 11 agreement between WORK Medical Technology and Shanghai Novabioplus Biotechnology for a joint development of intelligent medical models — a modest headline that in normal circumstances would barely register, but against a backdrop of thin float and elevated short positioning it was sufficient to trigger a cascade.
The ORTEX factor scores underscore how extreme this has become. The short score rank of 1 and utilization rank of 1 both place WOK at the absolute top of the squeeze-risk spectrum. Days-to-cover ranks in the 57th percentile — less extreme, but consistent with a situation where volume is now large enough relative to short interest that covering, in theory, is not impossible. What is impossible right now is finding fresh borrow: availability at zero means any short seller who needs to establish or maintain a position has no conventional route to do so.
Institutional ownership data confirms this is not a heavily institutionally sponsored name. Only three known holders appear in ORTEX records with a combined position of less than 3,500 shares — UBS Asset Management as the largest at 2,436 shares. The float dynamics are therefore driven almost entirely by retail flow and short positioning, which explains why the price and borrow market have moved so violently together.
What to watch next is whether availability opens back up — any softening in the borrow market from zero would signal the immediate squeeze pressure is easing — and whether the underlying AI-medical catalyst attracts follow-on news flow or fades quickly, which historically for nano-cap names of this size determines whether the post-squeeze stabilisation holds or reverses sharply.
See the live data behind this article on ORTEX.
Open WOK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
